Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
cNP8 · 1 trial · 1 indication
Clinical safety laboratory data will be collected
| Arm | Type | Description |
|---|---|---|
| Single ascending doses of cNP8 | EXPERIMENTAL | Subjects will be randomized to receive either a single dose of cNP8 or placebo (6:2). The doses will be studied sequentially starting with the lowest cNP8 dose. |
| Single doses of placebo administered | PLACEBO_COMPARATOR | Subjects will be randomized to receive either a single dose of cNP8 or placebo (6:2). |
| Name | Type | Description |
|---|---|---|
| cNP8 | DRUG | cNP8 for injection is provided as a sterile lyophilizate for solution for infusion. Subjects will receive a single 30 minute IV infusion of cNP8 at their assigned dose. |
| Placebo | OTHER | Subjects not randomized to cNP8 will receive a single 30 minute IV infusion of placebo. |
Inclusion Criteria: * BMI between 18 kg/m2 to 32 kg/m2 and body weight of greater than or equal to 50 kg. * Use of highly-effective methods of birth control * Willing and able to remain in a clinical research unit for the required study duration and return for the outpatient visit Exclusion Criter...
cNP8 is an investigational small molecule being developed for the treatment of burns. It is currently in Phase 1 clinical development, with a completed trial in healthy volunteers to evaluate its safety and tolerability. The drug is being studied in the United States.
cNP8 is being developed by United Therapeutics Corporation, a biotechnology company traded on the NASDAQ under the ticker symbol UTHR. The company is conducting clinical research on this investigational small molecule for the treatment of burns.
cNP8 is in Phase 1 clinical development. A Phase 1 study has been completed, which enrolled 32 participants. The drug is investigational and has not been approved by regulatory authorities. It is being studied for the treatment of burns.
cNP8 has one completed clinical trial, identified as NCT06223009, titled "Phase 1 Healthy Volunteer Burn Therapy Study." This was a randomized, double-blind, placebo-controlled trial conducted in the United States, enrolling 32 healthy volunteers aged 18 years and older.
No alternative names for cNP8 have been reported. The drug is identified solely as cNP8 in clinical trial records and is being developed by United Therapeutics Corporation for the treatment of burns.